Butyrate-mediated activation of GPR109A could upregulate anti-inflammatory effector molecules in colonic DCs and macrophages, which promoted the differentiation of IL-10-producing CD4+ T cells and Tregs, and inhibited the development of IL17-producing T cells, thereby preventing colitis and colon carcinogenesis [43]. This evidence concerns the gene IL10 and colitis.